[A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA]. Various molecular-targeted therapies were ineffective, so nivolumab treatment was started 12 years after the surgery.  Treatment was discontinued when the patient developed interstitial pneumonia after three courses of nivolumab treatment. 
nivolumab
[A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA]. Various molecular-targeted therapies were ineffective, so nivolumab treatment was started 12 years after the surgery.  Treatment was discontinued when the patient developed interstitial pneumonia after three courses of nivolumab treatment. 
nivolumab
[A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA]. Various molecular-targeted therapies were ineffective, so nivolumab treatment was started 12 years after the surgery.  Treatment was discontinued when the patient developed interstitial pneumonia after three courses of nivolumab treatment. 
nivolumab
[A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA]. Various molecular-targeted therapies were ineffective, so nivolumab treatment was started 12 years after the surgery.  Treatment was discontinued when the patient developed interstitial pneumonia after three courses of nivolumab treatment. 
nivolumab